UCB Ventures
Profile and portfolio
UCB Ventures is the corporate venture arm of UCB, a pharmaceutical and biotech company. It was founded in 2017 and is based in Brussels, Belgium. Sectors it names: biotech and life sciences.
- ExitsS3
- 2+
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| siRNA for CNS diseases | 1 | 7.1% |
| Non-viral genetic medicines | 1 | 7.1% |
| Protein splicing gene therapy | 1 | 7.1% |
| Cell therapy for neurological disorders | 1 | 7.1% |
| Kidney disease therapies | 1 | 7.1% |
| Stem cell therapy for hearing loss | 1 | 7.1% |
| VHH antiviral platform | 1 | 7.1% |
| Nanovesicle delivery | 1 | 7.1% |
| RNA therapeutics | 1 | 7.1% |
| Recombinase gene editing | 1 | 7.1% |
| Preeclampsia antibody | 1 | 7.1% |
| Ultrasound gene delivery | 1 | 7.1% |
| Acquired by AstraZeneca | 1 | 7.1% |
| Acquired by AbbVie | 1 | 7.1% |
A company can carry more than one tag
Sources: S3 UCB Ventures portfolio page.
Where it invests and who leads it
LeadersS2
- Erica WhittakerVice President and Head of UCB VenturesFind on LinkedInFirm page
- Alicia Irurzun-LafittePartnerFind on LinkedInFirm page
- Steven BiesmansPrincipalLinkedInFirm page
- Rahul KhetanVenture AssociateFind on LinkedInFirm page
Key facts
Portfolio
The firm's portfolio page lists 14 companies.S3
| Tag | Companies | Share |
|---|---|---|
| siRNA for CNS diseases | 1 | 7.1% |
| Non-viral genetic medicines | 1 | 7.1% |
| Protein splicing gene therapy | 1 | 7.1% |
| Cell therapy for neurological disorders | 1 | 7.1% |
| Kidney disease therapies | 1 | 7.1% |
| Stem cell therapy for hearing loss | 1 | 7.1% |
| VHH antiviral platform | 1 | 7.1% |
| Nanovesicle delivery | 1 | 7.1% |
| RNA therapeutics | 1 | 7.1% |
| Recombinase gene editing | 1 | 7.1% |
| Preeclampsia antibody | 1 | 7.1% |
| Ultrasound gene delivery | 1 | 7.1% |
| Acquired by AstraZeneca | 1 | 7.1% |
| Acquired by AbbVie | 1 | 7.1% |
Every company on the UCB Ventures list
14 companies, as listed on the firm's own website: 12 listed, 2 exited.S3 Read the firm's list.
Listed 12
- Beech Biotech
- Code Bio
- ExeVir Bio
- Iris Medicine
- Neurona Therapeutics
- Rinri Therapeutics
- Seamless Therapeutics
- SonoThera
- SpliceBio
- Switch Therapeutics
- ViaNautis
- Walden Biosciences
Exited 2
- EsoBiotec
- Syndesi Therapeutics
Official pages
Read the firm's own pages for current information.
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by UCB Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.